ZA966953B - Pharmaceutical composition. - Google Patents

Pharmaceutical composition.

Info

Publication number
ZA966953B
ZA966953B ZA9606953A ZA966953A ZA966953B ZA 966953 B ZA966953 B ZA 966953B ZA 9606953 A ZA9606953 A ZA 9606953A ZA 966953 A ZA966953 A ZA 966953A ZA 966953 B ZA966953 B ZA 966953B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical composition
stimulators
ifn
healing
gamma
Prior art date
Application number
ZA9606953A
Other languages
English (en)
Inventor
Mark William James Ferguson
Original Assignee
Univ Manchester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Manchester filed Critical Univ Manchester
Publication of ZA966953B publication Critical patent/ZA966953B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
ZA9606953A 1995-08-18 1996-08-16 Pharmaceutical composition. ZA966953B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9516967A GB2304342A (en) 1995-08-18 1995-08-18 Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma

Publications (1)

Publication Number Publication Date
ZA966953B true ZA966953B (en) 1998-02-16

Family

ID=10779448

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9606953A ZA966953B (en) 1995-08-18 1996-08-16 Pharmaceutical composition.

Country Status (13)

Country Link
EP (2) EP0845007B1 (pt)
JP (2) JP4070809B2 (pt)
AT (2) ATE231728T1 (pt)
AU (1) AU713809B2 (pt)
CA (1) CA2229590C (pt)
DE (2) DE69616803T2 (pt)
DK (2) DK0845007T3 (pt)
ES (2) ES2164911T3 (pt)
GB (1) GB2304342A (pt)
HK (1) HK1023516A1 (pt)
PT (2) PT972521E (pt)
WO (1) WO1997007136A2 (pt)
ZA (1) ZA966953B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1336654A1 (en) 1998-12-09 2003-08-20 Protein Design Labs, Inc. Method of treating psoriasis using anti-gamma interferon antibody
US6710025B1 (en) 1999-05-26 2004-03-23 The Brigham And Women's Hospital, Inc. Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin
JP2003500113A (ja) * 1999-05-26 2003-01-07 ザ ブリガム アンド ウイミンズ ホスピタル、 インコーポレイテッド アルファ平滑筋アクチン活性を調節する薬剤の治療的使用
US10080779B2 (en) 2004-12-15 2018-09-25 Universite D'angers Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM
WO2008099829A1 (ja) * 2007-02-14 2008-08-21 Japan Science And Technology Agency 実験動物の腸管癒着を形成する方法、腸管癒着実験動物の製造方法、腸管癒着抑制剤のスクリーニング方法及び腸管癒着抑制剤
GB0724231D0 (en) * 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
RU2539383C1 (ru) * 2013-11-29 2015-01-20 Закрытое акционерное общество "ФИРН М" (ЗАО "ФИРН М") Фармацевтическая композиция для лечения трофических язв и длительно незаживающих ран различной этиологии в виде мази

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78444A (en) * 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
WO1987007842A1 (en) * 1986-06-17 1987-12-30 Biogen N.V. Combinations of gamma interferons and anti-inflammatory or anti-pyretic agents and methods for treating diseases
NL8700927A (nl) * 1987-04-16 1988-11-16 Stichting Rega V Z W Anti-interferon-gamma-antilichamen; en hun therapeutische toepassing.
CA1335792C (en) * 1987-08-18 1995-06-06 Chaim O. Jacob Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders
IL88378A (en) * 1988-11-14 2000-11-21 Yeda Res & Dev Human interferon-gamma binding proteins their manufacture and pharmaceutical compositions comprising them
DE68927671T2 (de) * 1988-12-19 1997-05-07 American Cyanamid Co Produkte zur Behandlung des Endotoxin -Schocks bei einem Säugetier
GB8905400D0 (en) * 1989-03-09 1989-04-19 Jonker Margreet Medicaments
ATE132191T1 (de) * 1989-04-19 1996-01-15 Hoffmann La Roche Auflösbare interferon-gamma-rezeptoren sowie verfahren zu deren herstellung
IT1231727B (it) * 1989-08-11 1991-12-21 Enrico Savoldi Peptidi utili per la determinazione e la purificazione di anticorpi anti gamma interferone.
IL91562A0 (en) * 1989-09-07 1990-04-29 Yeda Res & Dev Interferon-gamma receptor fragment and its production
ATE132162T1 (de) * 1990-09-27 1996-01-15 Schering Corp Humane gammainterferonantagonisten
AU1462392A (en) * 1991-02-22 1992-09-15 Amgen, Inc. Use of gm-csf and g-csf to promote accelerated wound healing
NL9101290A (nl) * 1991-07-23 1993-02-16 Stichting Rega V Z W Recombinant dna-molecuul voor de expressie van een fv-fragment van een antilichaam.
DE4234380A1 (de) * 1992-10-06 1994-04-07 Schering Ag Verwendung von Dopaminagonisten zur Aktivierung des gamma-Interferon-Produktion
AU5669694A (en) * 1992-11-20 1994-06-22 Schering Corporation Antagonists of human gamma interferon
WO1994014467A1 (en) * 1992-12-29 1994-07-07 Genentech, Inc. Treatment of inflammatory bowel disease with ifn-gamma inhibitors
WO1995016036A2 (en) * 1993-12-09 1995-06-15 Michel Aguet IFN-ηRECEPTOR β-CHAIN AND DERIVATIVES THEREOF

Also Published As

Publication number Publication date
ATE231728T1 (de) 2003-02-15
ES2192018T3 (es) 2003-09-16
GB2304342A (en) 1997-03-19
WO1997007136A2 (en) 1997-02-27
EP0972521A1 (en) 2000-01-19
DK0845007T3 (da) 2001-12-17
EP0972521B1 (en) 2003-01-29
JP4616291B2 (ja) 2011-01-19
EP0845007A2 (en) 1998-06-03
AU713809B2 (en) 1999-12-09
WO1997007136A3 (en) 1997-08-21
DE69626050T2 (de) 2004-01-22
DE69616803D1 (de) 2001-12-13
DE69616803T2 (de) 2002-06-20
PT972521E (pt) 2003-06-30
GB9516967D0 (en) 1995-10-18
CA2229590C (en) 2010-10-12
JP4070809B2 (ja) 2008-04-02
ES2164911T3 (es) 2002-03-01
EP0845007B1 (en) 2001-11-07
HK1023516A1 (en) 2000-09-15
CA2229590A1 (en) 1997-02-27
JP2007119497A (ja) 2007-05-17
DE69626050D1 (de) 2003-03-06
JPH11511160A (ja) 1999-09-28
AU6707196A (en) 1997-03-12
ATE208402T1 (de) 2001-11-15
DK0972521T3 (da) 2003-05-05
PT845007E (pt) 2002-03-28

Similar Documents

Publication Publication Date Title
DE60018100D1 (en) Polymorphe form von atorvastatin-calcium
AU4133997A (en) Pharmaceutical composition for the treatment of syndrome x of reaven
AU1430492A (en) Pharmaceutical composition for the treatment of gastritis
MXPA94009086A (es) Guanidinas sustituidas terapeuticas.
GB9516012D0 (en) Pharmaceutical composition
GB9516967D0 (en) Pharmaceutical composition
AU623805B2 (en) New use of anti-progestomimetic compounds
IL111805A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of aphthae
AU1506692A (en) Pharmaceutical compositions
AU686084B3 (en) Pharmaceutical compositions for the treatment of depressive disorders
AU5494298A (en) Pharmaceutical compositions for the treatment of the eye
SI1083887T1 (sl) Farmacevtski sestavki za zdravljenje ulkusov
IL119250A (en) Pharmaceutical composition for the treatment of syndrome x of reaven
IL119403A0 (en) Pharmaceutical composition for the treatment of syndrome X of reaven
IL115200A0 (en) Pharmaceutical compositions for the treatment of cancer
UA15363A (uk) Засіб для лікуваhhя відкритих пошкоджеhь
IL116680A0 (en) Pharmaceutical composition for the treatment of depression
IL119219A0 (en) Pharmaceutical compositions for treatment of the eyes
IL122883A0 (en) Pharmaceutical compositions for the treatment of dyskinesias